Clinical Trials Directory

Trials / Completed

CompletedNCT01600352

Specific Autoantibody Testing in Patients With Interstitial Lung Disease

To Evaluate the Clinical Utility of Specific Autoantibody Testing in Patients With Interstitial Lung Disease

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Singapore General Hospital · Academic / Other
Sex
All
Age
21 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the clinical utility of specific autoantibody testing in unmasking an underlying connective tissue disorder in patients who present with interstitial lung disease and found to have weak positive ANA (1:400 titre) with no overt connective tissue disease manifestations OR borderline/negative ANA with some clinical suggestion of connective tissue disease.

Detailed description

It has been well established that patients with connective tissue disease associated interstitial lung disease respond better to immunosuppressive therapy, and have a better outcome compared to patients with idiopathic interstitial pneumonias. This makes it imperative to identify this group of patients for management and prognostication. Unfortunately some of these patients do not demonstrate overt clinical manifestations of connective tissue disease and our current available autoantibody screen does not detect all potential autoantibodies present. We would like to test for specific autoantibodies in this group of patients to evaluate its clinical utility in identifying covert connective tissue diseases associated with interstitial lung disease.

Conditions

Timeline

Start date
2012-05-01
Primary completion
2017-04-01
Completion
2017-04-01
First posted
2012-05-17
Last updated
2017-11-08

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT01600352. Inclusion in this directory is not an endorsement.